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The article presents a case of 57-year-old woman with the infiltration of rare small lymphocytic B cell lymphoma in
the thyroid gland. Initially, the patient was followed-up due to chronic lymphocytic B-cell leukemia diagnosed on
the basis of histopathological examination of cervical lymph node. Eight months later, general symptoms occurred
along with lymphocytosis and exacerbation of lesions in lymph nodes, and therefore, chemotherapy was started
according to COP regimen. After four chemotherapy cycles, further progression of the disease was observed during
chemotherapy. Computed tomography (CT) performed at that time showed generalized lymphadenopathy and the
presence of an irregular area in left thyroid lobe. On palpation, the thyroid was asymmetrical, with enlarged left
lobe and palpable lymph node packages on the left side of the neck. The levels of thyroid hormones and
anti-thyroid antibodies were normal. Ultrasound examination of the thyroid gland showed non-homogeneous
hypoechogenic structure of the left lobe and complete focal remodeling. Cytological examination of left-lobe lesion
obtained during fine needle aspiration biopsy showed multiple small lymphoid cells, suggestive of small
lymphocytic lymphoma. To confirm this diagnosis, flow cytometry of the biopsy material sampled from the left lobe
was performed showing B cellimmunophenotype: CD19+/CD20+/CD22 dim/FMC-7, CD23+/CD5+, sCD79b-+, CD38-
, CD10-, kappa and lambda-/weak reaction. The results of flow cytometry of the thyroid bioptate and blood were
nearly identical, confirming leukemic nature of the infiltration in left thyroid lobe. Cytogenetic findings included the
presence of 17p deletion (TP53 gene). The patient received immunochemotherapy with alemtuzumab. The
progression of the disease occurred in the sixth week of therapy. The treatment was discontinued after 8 weeks
due to worsening of patient’s general status. The patient died 15 months after the diagnosis.
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Lymphomas account for approximately 2% of all malig-
nancies of the thyroid gland, while the lymphomas with
primary location in the thyroid gland constitute about
2.5% of all lymphomas [1,2]. Normal thyroid gland does
not contain lymphatic tissue; its presence is characteris-
tic for pathological conditions, mainly as a result of the
transformation of autoimmune thyroiditis. Hashimoto’s* Correspondence: anhelli@asymed.ifg.pl
1Department of Endocrinology, Metabolic Diseases and Internal Diseases,
Pomeranian Medical University, ul. Unii Lubelskiej 1, 70-252, Szczecin, Poland
Full list of author information is available at the end of the article
© 2013 Andrysiak-Mamos et al.; licensee BioM
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumthyroiditis most often coexists with MALT (mucosa-
associated lymphoid tissue), which represents approxi-
mately 23% of thyroid lymphomas [2]. The most
frequent histologic type of thyroid lymphomas is diffuse
large B-cell lymphoma (DLCL), which accounts for
about 50% of all cases. Small lymphocytic B-cell lym-
phoma (SLL-B) is an extremely rare type of thyroid
lymphoma (about 4% of cases). According to the classifi-
cation presented by World Health Organization in 2008,
B-cell chronic lymphocytic leukemia (CLL-B) is a
leukemic form of SLL-B [3]. Pathological proliferation of
B-cells occurs in patients with CLL-B; these cellsed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Hormonal parameters of female patient with SLL-B/
CLL-B (at baseline and following 6-month follow-up)
Parameter Baseline Follow-up Reference range
TSH [mIU/ml] 1.70 1.4 0.27-4.2
fT4 [ng/dl] 1.73 1.49 0.93-1.7
fT3[pg/ml] 3.36 3.12 1.8-4.6
Anti-TPO [IU/ml] 5.7 4.10 0-34
Anti-TG [IU/ml] 12.9 9.17 0-115
LDH [U/L] 713 868 135-214
B2 microglobulin [mg/L] 6.23 8.16 0.2-2.0
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bone marrow, lymph nodes, spleen and – in very rare
cases – other organs [4,5]. This type of leukemia develops
in patients between 65 and 70 years of age, more fre-
quently in males, and it may remain asymptomatic for
extended time. General symptoms, such as excessive
sweating, weight loss, fever, and recurrent infections, in-
cluding opportunistic infections, may occur at the begin-
ning. Clinical picture includes lymphadenopathy and
enlargement of the spleen and the liver. Peripheral blood
cell count is characterized by leukocytic lymphocytosis;
while, thrombocytopenia and anemia, including auto-
immune hemolytic anemia, are less frequent [6]. Therapy
depends on clinical stage of the disease and the presence
of general symptoms. Apart from chemotherapy, immuno-
chemotherapy with anti-CD20 and anti-CD52 monoclonal
antibodies is used in the treatment of CLL-B.
Case presentation
In December 2011, a 57-year-old patient was referred to
Endocrinology Outpatient Clinic because of focal lesion
found on CT, which was located in left thyroid lobe. The
patient was monitored since March 2011 due to CLL-B.
The diagnosis was based on clinical manifestation and
histopathological examination of cervical lymph node. In
January 2011, bilateral enlargement of cervical and axillary
lymph nodes was found, without coexistent symptoms of
systemic infection. Histopathological and immunohisto-
chemistry findings in the specimen sampled from cervical
lymph node led to the diagnosis of small lymphocytic
B-cell lymphoma (SLL-B / CLL CD20(+), CD5(−), CD43
(+), CD(23+), MIB-1 (+) [10% of cells]). The patient
remained under the care of the Department of Hematology
at Pomeranian Medical University. Treatment was not
started, because the patient had no general symptoms and
the disease was classified as stage I in Rai staging system
(lymphocytosis and lymphadenopathy) as well as stage A in
Binet classification (fewer than three areas of lymphoid
involvement) [7]. Six months after the diagnosis, general
symptoms occurred (excessive sweating, subfebrile temper-
ature) together with the progression of changes in lymph
nodes and lymphocytosis. Chemotherapy according to COP
regimen (cyclophosphamide, vincristine, and prednisone)
was started, with each cycle lasting 21 days. After comple-
tion of 4 treatment cycles, general symptoms exacerbated
and progression of changes in the lymph nodes was found.
In December 2011 (10 months after the diagnosis), CT
revealed generalized lymphadenopathy (the enlargement of
cervical, axillary, mediastinal, retroperitoneal, and inguinal
lymph nodes) as well as the presence of an irregular, 22-
mm long area with calcifications located in left thyroid
lobe, which prompted endocrine diagnostic investigations.
On palpation, the thyroid was asymmetrical, with
enlarged left lobe and without palpable nodules oraudible thyroid bruit. Lymph node packages with the
diameter of 5 cm were palpable on the lateral surface of
the neck, particularly on its left side. Hormone tests
revealed normal levels of free thyroid hormones and
thyrotropin as well as normal levels of anti-thyroid per-
oxidase antibodies (anti-TPO), antithyroglobulin anti-
bodies (anti-TG), anti-TSH receptor antibodies (TRAK),
and normal thyroglobulin (TG) levels (Table 1). Ultra-
sound examination demonstrated asymmetry of the thy-
roid gland: left lobe was enlarged (59 × 23 × 21 mm),
while the right lobe was normal in size (44 × 11 ×
15 mm). The echostructure of the right lobe was hetero-
geneous with features of focal remodeling. Three focal
lesions were found with the size of 9 × 5 mm, 8 × 5 mm
and 12 × 11 mm (Figure 1). Left lobe had heterogeneous,
hypoechogenic structure and was focally remodeled in
its entirety. The largest focal lesion found in the left lobe
was 35 × 23 mm large, was poorly separated, being
solid–liquid in nature, and had heterogeneous, hypoe-
chogenic structure with calcifications (Figure 2). Power
Doppler ultrasound revealed vascularization of mixed
type. Additionally, two more focal lesions were found in
the left lobe: they were solid–liquid changes measuring
11 × 5 mm and 9 × 6 mm. Multiple packages of deeply
hypoechogenic lymph nodes without visualized vascular
hila and with pathologic vascularization were seen along
the sternocleidomastoid muscles in Power Doppler
ultrasound (Figure 3). Further diagnostic procedures
included fine needle aspiration biopsy of the dominant
lesion in left thyroid lobe, which showed multiple small
lymphoid cells and isolated hemosiderinophages among
blood constituents. Cytological picture of the lesion
located in the left lobe suggested the infiltration of small
lymphocytic lymphoma (Figure 4). The lesions found in
the right thyroid lobe were described as benign. To con-
firm the diagnosis, flow cytometry of the biopsy material
sampled from the focal lesion in left lobe was performed
(Pathomorphology Unit at the Faculty of Medicine,
Pomeranian Medical University in Szczecin) (Table 2). It
was concluded that atypical cells from the sampled
Figure 1 (a,b) Ultrasound image of right thyroid lobe with the features of nodular remodeling in 57-year-old female with SLL-B/CLL-B.
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CD22dim/FMC-7,CD23+/CD5+,sCD79b-+,CD38-,CD10-,
kappa and lambda - weak reaction (Figure 5). The results
of flow cytometry of the biopsy materials sampled from
the thyroid gland and blood were nearly identical. This
fact confirmed the leukemic nature of the infiltration in
left thyroid lobe.
Due to the progression of the disease during chemothe-
rapy, the diagnosis was re-verified, and suspicion was raised
of a possible transformation of the disease into more malig-
nant lymphoma. However, repeated histological examin-
ation of the lymph node, additional immunohistochemical
examinations, and imaging examinations confirmed the
diagnosis of CLL-B, also known as SLL-B. The patient also
underwent cytogenetic examinations, which demonstrated
the presence of 17p deletion (TP53 gene). The patient was
qualified for immunochemotherapy with alemtuzumab
(anti-CD52 monoclonal antibody). The treatment was
started in January 2012 at the Department of Hematology,Figure 2 (a,b) Ultrasound image of left thyroid lobe with the infiltrati
with SLL-B/CLL-B.Pomeranian Medical University in Szczecin, and it was con-
tinued at the Chemotherapy Day Unit of the Department
of Hematology. In the first weeks of treatment, the size of
lymph nodes was reduced below 50% of baseline values
and general symptoms resolved. Nevertheless, it should be
emphasized that the infiltration found in the left lobe did
not diminish in size, but instead slightly enlarged. Another
progression of the disease occurred in the sixth week of
treatment. After eight weeks, therapy was discontinued due
to further progression of the disease and deterioration in
patient’s general status. Despite anti-viral prophylactic mea-
sures, the patient developed generalized form of zoster. In
the course of further treatment, the patient was qualified
for palliative radiotherapy of lymph nodes. During radio-
therapy, the patient suffered from progressive paresis of the
limbs as the spinal cord became affected by the underlying
disease. The patient died 15 months after diagnosis due to
the progression of the disease, despite chemotherapy and
immunochemotherapy with alemtuzumab.on of small lymphocytic B-cell lymphoma in 57-year-old female
Figure 3 (a,b) Ultrasound image of cervical lymph node packages located along the sternocleidomastoid muscle in 57-year-old female
with SLL-B/CLL-B.
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mily for publication of this report and any accompanying
images.
Discussion
The case of SLL-B presented by our team belongs to the
least common subtypes of thyroid lymphoma. It is often
associated with the involvement of lymph nodes, bone
marrow, spleen, liver and – extremely rarely – other
organs. Our patient developed generalized lymphadeno-
pathy and the infiltration of left thyroid lobe, without
hepatosplenomegaly and with low-grade leukocytosis.
Similar location of changes and asymptomatic onset of theFigure 4 Cytological smear composed of cells somewhat larger
than small lymphocytes. The nuclei appear spherical, the
chromatin is coarsely granular and nuclei have regular contour. The
nucleoli are not prominent. Single hemosiderophages are visible.
The smears were fixed in alcohol and stained with hematoxylin-
eosin (×400).disease was described by Shin et al. in another female pa-
tient [8]. It is believed that the history of chronic auto-
immune Hashimoto’s thyroiditis predisposes to the
occurrence of lymphoma lesions in the thyroid [9,10].
According to literature, 80% of thyroid lymphomas are pre-
ceded by long-lasting (up to 20-30-year long) Hashimoto’s
thyroiditis [11]. This kind of thyroiditis particularly predis-
poses to the development of DLBCL lymphoma and MALT
lymphoma, and it may often hinder the assessment of cyto-
logical findings and make the final diagnosis difficult [1].
Our patient did not present autoimmune changes in the
thyroid gland or elevated levels of anti-thyroid antibodies
and thyroid dysfunction at the time of CLL-B diagnosis.
There are four reports in literature on small lympho-
cytic B-cell lymphoma (SLL-B/CLL-B), coexisting with
cancers or thyroiditis [8,12-14]. Two of the cases
described in literature involved the coexistence of SLL-
B/CLL-B and papillary cancer or papillary and medullary
cancer of the thyroid gland [12,13]. In the remaining
two cases described by Shin et al. [8] and Trümper et al.
[14], the development of lymphoma of the thyroid gland
was preceded by autoimmune thyroiditis with elevated
levels of anti-thyroid peroxidase antibodies and anti-
thyroglobulin antibodies [8,14]. Flow cytometry per-
formed in these cases and in our patient showed similar
expression of B-cell antibodies: CD20, CD19, CD5, and
CD23. Although our patient did not present biochemical
data indicative of autoimmune thyroiditis, ultrasound
image of left thyroid lobe might have suggested such diag-
nosis. It should be emphasized that the diagnosis of lym-
phoma based on fine needle aspiration biopsy is not always
possible; it may be especially difficult to establish its histo-
logic subtype and, consequently, to decide about further
treatment and prognosis. Core-needle biopsy, or intrao-
perative sampling of the specimens, is recommended
Table 2 Results of flow cytometry of fine needle biopsy specimen from the left thyroid lobe lesion
Type of cell Fraction [%]
Mature lymphocytes CD45++ (CD3 83.3%, CD4 69%, CD8 7.9%, CD5 90%) 2%
Neutrophils (16+/10-+/11c+/11b+/CD33-) 36%
Cellular conglomerates, debris, necrotic material (?) 25%
Atypical cells (larger, with large granules; some of them undergo apoptosis despite
retained antigen expression)
37%
Immunophenotype of atypical cells CD20 – 100%, CD23 – 98.6%, CD5 – 99.4%, CD79b – 32.5%,
CD22 – 41.8%, CD8 – 81.2%, CD56 – 91.4%, CD16 – 27.3%,
CD71 – 93.3%, CD19 – 60.7%, CD13 – 35.2%, FMC-7 31.3%.
Other antigens: CD3, CD4, CD38, CD11b, CD11c, CD10,
kappa, and lambda were negative.
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ful for the differentiation between Hashimoto’s thyroiditis,
lymphoma, and poorly differentiated or anaplastic cancer
of the thyroid. It is easier to arrive at the final diagnosis of
focal thyroid lesions, if the patient already has the history
of CLL-B, as it was the case in our patient. It may alsoThe small neoplastic cells (CD45+)
 - leucocytes
Small cells (CLL-B) with bright CD5 expression
a
c
Figure 5 (a-d) Flow cytometry interpretation. The neoplastic cells displa
bright CD23 and CD5 expression. Some of the tumor cells have features of
aggressive with azurophilic granules within cytoplasm. Yellow: CD3+/CD4-/happen that thyroid changes are diagnosed first and only
later the diagnosis of SLL-B/CLL-B is established [8,12].
The treatment of primary lymphomas of the thyroid
gland, as well as infiltration changes associated with CLL-
B, remains controversial. The recommended strategy
includes chemotherapy, radiotherapy, and in particularLymphocytes B (CLL-B) with expression of 
CD 23+ and CD22+ antigens
Some of the tumor cell have features of 
atypia and expression of CD8+
b
d
y the typical antigenic features of CLL including small cell size and
atypia and express CD8; these cells are considered to be more
CD8-; dark-blue: CD3+; red: CD23+/CD22 + dim; green: CD79b + dim.
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clonal antibodies. Our patient did not respond to chemo-
therapy and progression of the disease was observed
during treatment. Because of genetic background of the
disease (17p13 deletion TP53 gene), alemtuzumab (anti-
CD52 monoclonal antibody) was started. Nearly 5% of
patients show 17p13 deletion at the time of CLL-B diag-
nosis, but during the course of the disease 17p13 deletion
is found in almost 50% of the patients. These genetic
changes are associated with the resistance to standard
treatment and they are an unfavorable prognostic factor
[16,17]. The use of alemtuzumab in patients with CLL-B
and 17p13 deletion caused positive response only in 40%
patients [18]. This drug is also recommended in patients
with CLL-B and other genetic disorders, e.g. 11q22 dele-
tion (positive response in 27% patients) [19]. In our patient,
alemtuzumab treatment did not result in the regression of
thyroid lesions, despite good initial response to the treat-
ment as was reflected in the reduced size of lymph nodes.
Dynamic progression of the disease and 15-month long
survival despite treatment are likely to be associated with
genetic background of the disease, the presence of TP53
gene mutation – 17p deletion, which, as many authors
emphasize, is an unfavorable prognostic factor.
Conclusions
The occurrence of small lymphocytic B-cell lymphoma
(SLL-B) in the thyroid gland associated with CLL-B may
not be preceded by autoimmune thyroiditis (Hashimoto’s
thyroiditis).
Thyroid lesions associated with SLL-B/CLL-B do not
respond to treatment (chemotherapy and immunochem-
otherapy – with alemtuzumab).
The presence of 17p deletion is an unfavorable prog-
nostic factor in patients with SLL-B/CLL-B.
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